Interesting Images68Ga–Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer A Case ReportPilati, Emanuela MD; Nicolotti, Daniele Giovanni MD; Ceci, Francesco MD, PhD; Finessi, Monica MD; Cerio, Ivan MD; Dionisi, Beatrice MD; Zotta, Michela MD; Bellò, Marilena MD; Deandreis, Désirée MD, APAuthor Information From the Division of Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, Italy. Received for publication June 27, 2019; revision accepted October 7, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Emanuela Pilati, MD, Division of Nuclear Medicine, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy. E-mail: email@example.com. Online date: December 24, 2019 Clinical Nuclear Medicine: March 2020 - Volume 45 - Issue 3 - p e151-e153 doi: 10.1097/RLU.0000000000002884 Buy Metrics Abstract Prostate-specific membrane antigen (PSMA) is a transmembrane enzyme also known as folate hydrolase 1 highly expressed by prostate cancer (PCa) cells. However, PSMA overexpression by tumor-associated neovasculature of a variety of solid tumors, including glioblastoma (GBM), has also been proven. This clinical case reports about a 67-year-old man with a history of PCa who underwent radical surgery for GBM and performed a 68Ga-PSMA-11 PET/CT to restage PCa. PET imaging showed PSMA uptake in GBM residual disease after surgery. This finding suggests a possible role of PSMA inhibitors as diagnostic and therapeutic agents in patients affected by GBM. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.